Next Frontiers in Urology: a Biennial AUA/JUA Symposium: Advancements in Urology (2019)
Join the AUA, the JUA and some of today’s global leaders in urologic medicine for an in-depth look at the latest advances in urology!
This biennial symposium gathers esteemed faculty and leadership from both the American Urological Association (AUA) and the Japanese Urological Association (JUA). Join us to network with your colleagues and get the latest updates in clinical guidelines and new and emerging treatment options in urologic medicine.
Urologists and those practicing urology need a thorough knowledge of the most recent developments and techniques in urology to ensure the highest standards of patient care and safety. This course is designed to inform on the latest in medical and surgical management of the areas deemed most essential to urologists, including urologic oncology (prostate, bladder and kidney), urolithiasis, BPH & LUTS, voiding dysfunction and pediatrics.
Next Frontiers in Urology: a Biennial AUA/JUA Symposium is supported by independent educational grants from:
- Boston Scientific
- Bristol-Myers Squibb
- Genomic Health
- Olympus Corporation of the Americas
- Pfizer, Inc.
- UroGen Pharma
- Advanced practice providers
Upon completion of this course, attendees will be able to:
Session I - Prostate Cancer
- Review the use of genomic biomarkers and genetic testing in the prognostication of advanced prostate cancer.
- Describe via an AUA Guidelines-based approach the management of castration resistant prostate cancer (CRPC) and outline a coherent strategy for their use.
- Detail the new therapeutic interventions for metastatic and non-metastatic castration resistant prostate cancer (CRPC).
- Provide new evidence on the role of immunotherapy in prostate cancer.
Session II - Bladder and Upper Tract Urothelial Carcinoma
- Identify and describe technological advances that facilitate the endoscopic management of bladder cancer.
- Discuss the therapeutic role of immunotherapy in bladder cancer.
- Update clinicians on new clinical trials with emerging treatments and possible complications.
Session III - Renal Cancer
- Define the role of combination therapy for intermediate and poor risk advanced renal cancer.
- Describe the role of adjuvant therapy in high risk renal cancer patients following nephrectomy.
- Detail the possible adverse events of medical therapy of advanced renal cancer.
- Discuss case scenarios and real-world management decisions for renal cancer.
Session IV - Urolithiasis
- Detail evidence-based guidelines for medical and dietary kidney stone prevention and surgical treatment.
- Identify new technology to optimize outcomes and minimize complications.
- Utilize a case-based/video approach to understand difficult clinical scenarios.
Session V - BPH & LUTS
- Describe current guidelines for the assessment and surgical treatment of LUTS in men.
- Differentiate the new and evolving technology and techniques for treatment of BPH.
Session VI - Urinary Incontinence, Voiding dysfunction and Prolapse Management
- Describe strategies for urinary incontinence and pelvic organ prolapse in women including indications and outcomes.
- Compare conservative and surgical treatment options for men with post prostatectomy incontinence.
- Describe pharmacologic combination therapy for overactive bladder (OAB).
Session VII - Pediatric Urology
- Describe management strategies for common pediatric conditions.
Wednesday, February 6, 2019
|1:00 – 2:00 p.m.||Early Registration in Luskin Conference Center|
|2:00 p.m.||Hospital Tours (JUA Young Urologists)|
|3:30 p.m.||Residents Networking Reception|
Athletics Hall of Fame
Residents Networking Event
UCLA vs. Colorado Men's Basketball Game
Thursday, February 7, 2019
|6:30 – 7:30 a.m.||Registration, Continental Breakfast & Poster Viewing|
|7:30 – 7:40 a.m.||Opening Remarks|
Robert C. Flanigan, MD, FACS, AUA President
Masato Fujisawa, MD, PhD, JUA President
Mark S. Litwin, MD, MPH, Chair, UCLA Department of Urology
|7:40 – 7:45 a.m.||Welcome|
Sam S. Chang, MD, MBA, AUA Assistant Secretary & Symposium Course Director
Session I – Prostate Cancer
|7:45 – 8:05 a.m.||Biomarkers for Treatment Decision for Advanced Prostate Cancer|
Naohiro Fujimoto, MD, PhD
|8:05 – 8:25 a.m.||Update on Castration-Resistant Prostate Cancer (CRPC) Guideline|
Daniel W. Lin, MD
|8:25 – 8:50 a.m.||Update in the Treatment of mCRPC|
Hiroji Uemura, MD, PhD
|8:50 – 9:15 a.m.||Update in the Treatment of nmCRPC|
Robert Reiter, MD
|9:15 – 9:25 a.m.||Immunotherapy for Prostate Cancer|
Robert Reiter, MD
|9:25 – 9:40 a.m.||Break|
|9:40 – 11:00 a.m.||Panel Discussion: Case Management|
Moderators: Sam S. Chang, MD, MBA & Tsukasa Igawa, MD, PhD
Panelists: Naohiro Fujimoto, MD, PhD; Daniel W. Lin, MD; Will Lowrance, MD; Robert Reiter, MD; Hiroji Uemura, MD, PhD
Session II – Bladder Cancer and Upper Tract Urothelial Carcinoma
|11:00 – 11:20 a.m.||Cystoscopic Techniques for the Identification of Bladder Cancer|
Arnold I. Chin, MD, PhD
|11:20 – 11:40 a.m.||Immunotherapy for Bladder Cancer|
Will Lowrance, MD
|11:40 a.m. – 12:10 p.m.||Update on Clinical Trials and Emerging Treatments|
Hiroshi Kitamura, MD, PhD
|12:10 – 1:25 p.m.|
“A Treatment Option for Castration-Resistant Prostate Cancer (CRPC)”
Non-CME Lunch Symposium supported by Astellas Pharma US, Inc. and Pfizer Oncology
|1:25 – 1:45 p.m.||Adverse Effects of Newly Approved and Emerging Treatments|
Isao Hara, MD, PhD
|1:45 – 2:35 p.m.||Video Session: Robot-assisted Radical Cystectomy (RARC)|
Surgeon: Karim Chamie, MD
Panelists: Sam S. Chang, MD, MBA; Arnold I. Chin, MD, PhD; Isao Hara, MD, PhD; Hiroshi Kitamura, MD, PhD; Will Lowrance, MD
Session III – Renal Cancer
|2:35 – 2:55 p.m.||Combination Therapy for Previously Untreated Patients with Intermediate and Poor Risk Advanced RCC|
Hirotsugu Uemura, MD, PhD
|2:55 – 3:15 p.m.||Adjuvant Treatment of Patients at High Risk of Recurrent RCC Following Nephrectomy|
Robert C. Flanigan, MD, FACS
|3:15 – 3:30 p.m.||Break|
|3:30 – 4:20 p.m.||Video Session: Robot-assisted Partial Nephrectomy (RAPN)|
Surgeon: Brian Shuch, MD
Panelists: Robert C. Flanigan, MD, FACS; Yoshihiko Tomita, MD, PhD; Hirotsugu Uemura, MD, PhD
|4:20 – 5:00 p.m.||Panel Discussion: Case Management|
Moderators: Robert C. Flanigan, MD, FACS & Yoshihiko Tomita, MD, PhD
Panelists: Karim Chamie, MD; Masatoshi Eto, MD, PhD; Tsunenori Kondo, MD, PhD; Brian Shuch, MD
|5:00 – 6:00 p.m.||Grand Rounds I|
|6:00 – 7:30 p.m.||Networking Reception|
Friday, February 8, 2019
|6:00 – 6:45 a.m.||Registration, Continental Breakfast & Poster Viewing|
|6:45 – 6:50 a.m.|
Masato Fujisawa, MD, PhD, JUA President
Session IV – Urolithiasis
|6:50 – 7:10 a.m.||Stone Disease Guidelines Update: Surgical|
John Denstedt MD, FRCSC, FACS
|7:10 – 7:30 a.m.||New Technology in the Management of Stone Disease|
Ryan Hsi, MD
|7:30 – 7:45 a.m.||Medical and Dietary Stone Prevention|
Shuzo Hamamoto, MD, PhD
|7:45 – 8:30 a.m.||Video Session: PCNL|
Surgeon: Matt Dunn, MD
Panelists: John Denstedt MD, FRCSC, FACS; Ryan Hsi, MD; Yasuo Kohjimoto, MD, PhD; Yukio Naya, MD, PhD
Session V – BPH & LUTS
|8:30 – 8:50 a.m.||Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline|
Matt Dunn, MD
|8:50 – 9:10 a.m.||Comparison of Surgical Treatment Options|
Naoya Masumori, MD, PhD
|9:10 – 9:25 a.m.||Break|
Session VI – Urinary Incontinence, Voiding Dysfunction and Prolapse Management
|9:25 – 9:45 a.m.||Management Strategies for Incontinence and Prolapse|
Victor W. Nitti, MD
|9:45 – 10:05 a.m.||Treatment of Overactive Bladder – Focus on Pharmacological Combination Therapy|
Masaki Yoshida, MD, PhD
Session VII – Pediatric Urology
|10:05 – 10:45 a.m.||Video Session: Robot-assisted Pyeloplasty|
Surgeon: Matt Dunn, MD
Panelist: Yutaro Hayashi, MD, PhD
|10:45 – 11:45 a.m.||Grand Rounds II|
|11:45 a.m. – 12:55 p.m.||Lunch|
|12:55 – 1:00 p.m.||Closing Remarks|
Yoshihiko Tomita, MD, PhD, Symposium Course Director
|1:00 – 3:00 p.m.||Non-CME Skills Workshop|
|3:00 p.m.||Hospital Tours (JUA Faculty)|
The AUA recommends that you register for the course BEFORE making travel arrangements. Once the meeting capacity is reached, which may be prior to the early-bird date, the AUA is unable to guarantee a spot in the course.
UCLA Meyer and Renee Luskin Conference Center of its Los Angeles Campus
Rooms start at $259 single/double occupancy. Please call 1-855-LCC-UCLA (522-8252) and reference the American Urological Association when making your reservation to receive the special group rate. To hold a reservation, a major credit card number must be provided.
Please note: To receive the discounted group rate, you must book directly via our online link OR call the hotel and reference the AUA by January 7, 2019.
Cut-off Date: Monday, January 7, 2019. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.
Check-in: 4 p.m.
Check-out: 12 p.m.
Parking is available at the hotel and conference center, as well as around campus in multiple areas.
For More Information - https://luskinconferencecenter.ucla.edu/about/campus-map-parking/
From Los Angeles International Airport
Take the San Diego Freeway (I-405) North and exit at Wilshire Boulevard East. Turn right onto Wilshire Boulevard and proceed a half mile to Westwood Boulevard. Turn left and the UCLA Luskin Conference Center is located one mile ahead at end of the turnaround.
From Alternate Airports
Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code CV# 053G0001.
Breakfast, lunch and coffee breaks will provided on both days of the meeting. Join us for a networking reception on Thursday, February 7, 2019.
Business casual dress is encouraged. Attendees may want to bring a sweater or jacket, as meeting rooms can be chilly.
The average temperatures in Los Angeles during February are a high of 69 degrees Fahrenheit/ 21 degrees Celsius and a low of 50 degrees Fahrenheit/ 10 degrees Celsius.
There’s always something special happening in Southern California, and at UCLA, you’ll feel at the center of it all. Buzzing with activity, culture, athletics, academics and research, the campus is set against the exciting backdrop of Los Angeles. Please click here to explore the many possibilities that both UCLA and Southern California have to offer during your stay!
Education Council Disclosures
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 13.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.
Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
- 13.25 AMA PRA Category 1 Credit™
- 13.25 Non-Physician Participation
AUA & JUA Members save 25%! For more information on membership benefits, visit .
Register on or before December 21, 2018 to save 25%!
Early Bird On or Before
December 21, 2018
Standard On or After
December 22, 2018
If you are a JUA Member and are not able to see the JUA Member rate, please contact Helen Scofield at HScofield@AUAnet.org to receive the reduced JUA Member rate.
An administrative fee of 15% is assessed if registration is cancelled up to six weeks prior to the course. If registration is cancelled four to six weeks from the course, the cancellation fee is 50% of the registration fee paid. No registration fees will be refunded less than four weeks prior to the course.
Customers switching from an option of lesser value to a higher value will be required to pay the difference in cost between the two options. Switching to an option of lesser value from a higher value must be made no later than to six weeks prior to the course and will be subject to an administrative fee of 15% of the cost of the course from which they are transferring. Transfer of registration from a higher value option to an option of lesser value past six weeks prior to the course will not receive a refund.
Cancellations must be made in writing. Requests may be made via mail or fax to 410-689-3912. Questions? Call 1-800-908-9414 or email registration@AUAnet.org.
AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before January 4, 2019. If AUA Education & Research cancels this course, registration fees will be refunded in full and notification will be sent by January 11, 2019.